Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roniciclib + Docetaxel in 2nd/3rd Line Advanced NSCLC
NCT02522910Phase 2Withdrawn
- Sponsor
- Yonsei University
- Start
- Aug 2015
- Primary completion
- Aug 2016
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of roniciclib in non-small cell lung cancer (NSCLC), sponsored by Yonsei University. Primary endpoints: Maximum Tolerated Dose at 4 months, Dose-Limiting Toxicities at 4 months and 1 more. Planned start Aug 2015; status: withdrawn.
02
Drugs
roniciclib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02522910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02522910.